| Univariate Analysis | Multivariate Analysis | ||||
---|---|---|---|---|---|---|
Variable | Hazard ratio | 95% C.I. | P | Hazard ratio | 95% C.I. | P |
Age, years (continuous) | 1.01 | 0.96-1.06 | 0.78 | - | - | - |
Gender (female [n = 12] vs male [n = 40]) | 0.48 | 0.11-2.10 | 0.33 | - | - | - |
Stage (UICC II and higher [n = 32] vs. UICC I [n = 20]) | 3.72 | 1.07-12.98 | 0.04 | 2.00 | 0.42-9.09 | 0.39 |
Grade (3+4 [n = 22] vs. 1+2 [n = 30]) | 1.43 | 0.55-3.71 | 0.46 | - | - | - |
T category (T3/T4 [n = 8] vs. T1/T2 [n = 44]) | 2.48 | 0.80-7.68 | 0.11 | - | - | - |
N category (. N+ [n = 28] vs N0 [n = 24]) | 3.27 | 1.06-10.02 | 0.04 | 2.04 | 0.51-8.33 | 0.32 |
Number of metastatic lymph nodes (continuous) | 1.35 | 1.17-1.56 | <0.001 | - | - | - |
TILs and macrophages in primary tumour site (high vs. low) | ||||||
 | Hazard ratio | 95% C.I. | P | Hazard ratio | 95% C.I. | P |
Intraepithelial | Â | Â | Â | Â | Â | Â |
CD3+ TIL | 0.76 | 0.29-1.98 | 0.58 | - | - | - |
CD8+ TIL | 1.26 | 0.48-3.32 | 0.63 | - | - | - |
CD20+ TIL | 2.05 | 0.79-5.32 | 0.14 | - | - | - |
CD68+ TIM | 0.69 | 0.27-1.80 | 0.45 | - | - | - |
FoxP3+ TIL | 0.78 | 0.30-2.03 | 0.61 | - | - | - |
Granzyme B+ TIL | 0.72 | 0.21-2.53 | 0.61 | - | - | - |
Stromal | Â | Â | Â | - | - | - |
CD3+ TIL | 0.86 | 0.33-2.23 | 0.76 | - | - | - |
CD8+ TIL | 0.85 | 0.33-2.20 | 0.74 | - | - | - |
CD20+ TIL | 0.80 | 0.31-2.08 | 0.65 | - | - | - |
CD68+ TIM | 0.81 | 0.31-2.10 | 0.66 | - | - | - |
FoxP3+ TIL | 0.23 | 0.08-0.72 | 0.01 | 0.25 | 0.08-0.78 | 0.016 |
Granzyme B+ TIL | 0.87 | 0.33-2.29 | 0.78 | - | - | - |
Ratio stromal CD68 (primary tumour)/stromal FoxP3 (primary tumour) | 4.02 | 1.31-12.36 | 0.02 | Â | Â | Â |
TIL and macrophages in metastatic tissue (high vs. low) | ||||||
Intraepithelial | Hazard ratio | 95% C.I. | P | Â | Â | Â |
   CD3+ TIL | 0.32 | 0.09-1.12 | 0.07 |  |  |  |
   CD8+ TIL | 1.14 | 0.35-3.76 | 0.83 |  |  |  |
   CD20+ TIL | 0.20 | 0.03-1.58 | 0.13 |  |  |  |
   CD68+ TIM | 0.96 | 0.29-3.16 | 0.95 |  |  |  |
   FoxP3+ TIL | 0.58 | 0.17-1.99 | 0.39 |  |  |  |
   Granzyme B+ TIL | 0.88 | 0.19-4.09 | 0.87 |  |  |  |
Stromal | Â | Â | Â | Â | Â | Â |
   CD3+ TIL | 0.61 | 0.19-2.03 | 0.42 |  |  |  |
   CD8+ TIL | 1.16 | 0.35-3.81 | 0.81 |  |  |  |
   CD20+ TIL | 0.51 | 0.15-1.75 | 0.28 |  |  |  |
   CD68+ TIM | 1.30 | 0.40-4.28 | 0.66 |  |  |  |
   FoxP3+ TIL | 0.81 | 0.25-2.69 | 0.74 |  |  |  |
   Granzyme B+ TIL | 0.75 | 0.23-2.46 | 0.63 |  |  |  |
Lymphocytes and macrophages in uninvolved regional lymph node (high vs. low) | ||||||
 | Hazard ratio | 95% C.I. | P |  |  |  |
CD3+ | 0.47 | 0.17-1.26 | 0.13 | Â | Â | Â |
CD8+ | 0.84 | 0.32-2.19 | 0.72 | Â | Â | Â |
CD20+ | Â | Â | Â | Â | Â | Â |
CD68+ | 0.56 | 0.21-1.47 | 0.24 | Â | Â | Â |
FoxP3+ | 1.03 | 0.40-2.68 | 0.95 | Â | Â | Â |
Granzyme B+ | 0.35 | 0.12-0.99 | 0.05 | Â | Â | Â |